SummitTX Capital’s Kura Oncology KURA Stock Holding History

SummitTX Capital’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,106	Closed	-$86.5K	–	898
2025 Q1	$86.5K	Buy	+13,106	New	+$102K	﹤0.01%	761

Other funds holding KURA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SummitTX Capital's KURA Position: Q2 2025 in Review

SummitTX Capital sold out of Kura Oncology (KURA) in Q2 2025, closing a stake of 13,106 shares — an estimated $86.5K sold.

SummitTX Capital first reported a position in KURA in Q1 2025 and held it in 1 quarter. The position peaked at $86.5K in Q1 2025. 182 funds tracked by Wall St. Rank hold KURA as of Q2 2025.

SummitTX Capital reported no remaining Kura Oncology position as of Q2 2025 after selling out during the quarter.
SummitTX Capital sold 13,106 Kura Oncology shares in Q2 2025, an estimated $86.5K.
SummitTX Capital first reported a position in Kura Oncology in Q1 2025 and held it in 1 quarter.
SummitTX Capital's Kura Oncology position peaked at $86.5K in Q1 2025.
182 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2025.

Based on SummitTX Capital's 13F filing for Q2 2025, filed 14 Aug 2025.